Suppr超能文献

瑞典13896例多发性骨髓瘤患者的37838名一级亲属中血液系统恶性肿瘤和实体瘤的发病模式。

Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.

作者信息

Kristinsson Sigurdur Y, Björkholm Magnus, Goldin Lynn R, Blimark Cecilie, Mellqvist Ulf-Henrik, Wahlin Anders, Turesson Ingemar, Landgren Ola

机构信息

Department of Medicine, Division of Hematology, Karolinska University Hospital, Solna and Karolinska Institutet, Stockholm, Sweden.

出版信息

Int J Cancer. 2009 Nov 1;125(9):2147-50. doi: 10.1002/ijc.24514.

Abstract

There are emerging data to suggest a role for genetic factors in the pathogenesis of multiple myeloma (MM). Based on small numbers, certain solid tumors have been reported to occur more frequently among blood relatives of patients with MM. Using population-based data, we assessed risks for hematologic malignancies, monoclonal gammopathy of undetermined significance (MGUS), and solid tumors among first-degree relatives of patients with MM. We included 13,896 patients with MM and 54,365 matched controls. Also we identified first-degree relatives of patients with MM (n = 37,838) and controls (n = 151,068). Using a marginal survival model, we estimated relative risks (RRs) and 95% confidence intervals (CIs) for hematologic and solid tumors among family members of patients with MM and controls as measures of familial aggregation. Compared with relatives of controls, relatives of patients with MM had an increased risk of developing MM (RR = 2.1; 95% CI 1.6-2.9), MGUS (2.1; 1.5-3.1), acute lymphoblastic leukemia (ALL) (2.1; 1.0-4.2), any solid tumor (1.1; 1.0-1.1) and bladder cancer (1.3; 1.0-1.5). No significantly increased risk was found for other hematologic or solid malignancies. Our findings support a role for a shared susceptibility (genetic, environmental or both) that predisposes to MM, MGUS, ALL and bladder cancer.

摘要

越来越多的数据表明遗传因素在多发性骨髓瘤(MM)的发病机制中起作用。基于少量病例报告,某些实体瘤在MM患者的血亲中更频繁发生。利用基于人群的数据,我们评估了MM患者一级亲属中血液系统恶性肿瘤、意义未明的单克隆丙种球蛋白病(MGUS)和实体瘤的发病风险。我们纳入了13896例MM患者和54365例匹配对照。我们还确定了MM患者(n = 37838)和对照(n = 151068)的一级亲属。使用边际生存模型,我们估计了MM患者和对照家庭成员中血液系统和实体瘤的相对风险(RR)及95%置信区间(CI),作为家族聚集性的衡量指标。与对照的亲属相比,MM患者的亲属患MM(RR = 2.1;95%CI 1.6 - 2.9)、MGUS(2.1;1.5 - 3.1)、急性淋巴细胞白血病(ALL)(2.1;1.0 - 4.2)、任何实体瘤(1.1;1.0 - 1.1)和膀胱癌(1.3;1.0 - 1.5)的风险增加。未发现其他血液系统或实体恶性肿瘤的风险有显著增加。我们的研究结果支持存在一种共同易感性(遗传、环境或两者兼有),它易导致MM、MGUS、ALL和膀胱癌。

相似文献

10
Familial aggregation of Hodgkin lymphoma and related tumors.
Cancer. 2004 May 1;100(9):1902-8. doi: 10.1002/cncr.20189.

引用本文的文献

1
Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma.
Blood Neoplasia. 2024 Oct 12;2(1):100045. doi: 10.1016/j.bneo.2024.100045. eCollection 2025 Feb.
4
The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.
Pharmgenomics Pers Med. 2024 Dec 21;17:573-609. doi: 10.2147/PGPM.S350238. eCollection 2024.
5
FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.
Semin Hematol. 2025 Feb;62(1):11-19. doi: 10.1053/j.seminhematol.2024.11.006. Epub 2024 Nov 30.
6
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
Blood Cancer Discov. 2024 Nov 1;5(6):428-441. doi: 10.1158/2643-3230.BCD-23-0208.
7
Addressing the disparities: the approach to the African American patient with multiple myeloma.
Blood Cancer J. 2023 Dec 18;13(1):189. doi: 10.1038/s41408-023-00961-0.
9
Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.
Front Immunol. 2022 Apr 28;13:876271. doi: 10.3389/fimmu.2022.876271. eCollection 2022.

本文引用的文献

3
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.
Blood. 2009 May 28;113(22):5412-7. doi: 10.1182/blood-2008-12-194241. Epub 2009 Jan 29.
4
Familial myeloma.
N Engl J Med. 2008 Oct 16;359(16):1734-5; author reply 1735. doi: 10.1056/NEJMc081677.
6
Familial myeloma.
N Engl J Med. 2008 Jul 10;359(2):152-7. doi: 10.1056/NEJMoa0708704.
8
Multiple myeloma.
Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022.
9
Clinically relevant end points and new drug approvals for myeloma.
Leukemia. 2008 Feb;22(2):231-9. doi: 10.1038/sj.leu.2405016. Epub 2007 Nov 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验